TechFlex is dedicated to assisting startups in the Series A and Seed money stages to achieve their objectives through a structured and supportive framework. Our approach focuses on providing tailored solutions that address the unique challenges faced by early-stage companies.
TechFlex is the catalyst for success in the medical device industry, offering comprehensive support to growing companies. With expertise spanning from initial concept to market entry, TechFlex provides tailored solutions, cutting-edge technologies, and regulatory guidance.
The Food and Drug Administration released a final rule Sept. 18 that rescinds one from 2024 that applied medical device rules to laboratory-developed tests. The final rule is in response to a March 31 federal district court decision that also vacated the FDA’s 2024 final rule.
Read the full article at: www.aha.org
